04:01 PM EST, 12/08/2025 (MT Newswires) -- Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the Health Care Select Sector SPDR Fund (XLV) falling 1.2%.

The iShares Biotechnology ETF (IBB) decreased 0.5%.

In corporate news, Kamada ( KMDA ) shares dropped 5% after it said Monday that it will discontinue the phase 3 trial of inhaled AAT for the treatment of Alpha-1 Antitrypsin Deficiency due to the "low likelihood of a successful efficacy outcome."

BiomX ( PHGE ) tumbled 36% after it reported a discontinuation of a phase 2b trial of nebulized phage therapy, BX004, in patients with CF associated with chronic Pseudomonas aeruginosa infections.

STAAR Surgical ( STAA ) shares fell 7% after the company said Monday the go-shop period under its merger agreement with Alcon ( ALC ) has expired with no competing proposals received. Alcon ( ALC ) was down 2.1%.

PROCEPT BioRobotics ( PRCT ) still has a large market opportunity for its aquablation technology to treat benign prostatic hyperplasia, but utilization growth has slowed, BofA Securities said in a report. It downgraded the stock to neutral from buy and cut its price target to $38 from $55. PROCEPT fell 4.5%.